99 related articles for article (PubMed ID: 7753547)
1. Oligomerisation of full length p53 contributes to the interaction with mdm2 but not HPV E6.
Marston NJ; Jenkins JR; Vousden KH
Oncogene; 1995 May; 10(9):1709-15. PubMed ID: 7753547
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation.
Alarcón R; Koumenis C; Geyer RK; Maki CG; Giaccia AJ
Cancer Res; 1999 Dec; 59(24):6046-51. PubMed ID: 10626788
[TBL] [Abstract][Full Text] [Related]
3. Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function.
Marston NJ; Crook T; Vousden KH
Oncogene; 1994 Sep; 9(9):2707-16. PubMed ID: 8058335
[TBL] [Abstract][Full Text] [Related]
4. Differences in the ubiquitination of p53 by Mdm2 and the HPV protein E6.
Camus S; Higgins M; Lane DP; Lain S
FEBS Lett; 2003 Feb; 536(1-3):220-4. PubMed ID: 12586367
[TBL] [Abstract][Full Text] [Related]
5. p53 in complex with DNA is resistant to ubiquitin-dependent proteolysis in the presence of HPV-16 E6.
Molinari M; Milner J
Oncogene; 1995 May; 10(9):1849-54. PubMed ID: 7753560
[TBL] [Abstract][Full Text] [Related]
6. Multiple lysine mutations in the C-terminus of p53 make it resistant to degradation mediated by MDM2 but not by human papillomavirus E6 and induce growth inhibition in MDM2-overexpressing cells.
Nakamura S; Roth JA; Mukhopadhyay T
Oncogene; 2002 Apr; 21(16):2605-10. PubMed ID: 11971195
[TBL] [Abstract][Full Text] [Related]
7. Proteasomal degradation of p53 by human papillomavirus E6 oncoprotein relies on the structural integrity of p53 core domain.
Bernard X; Robinson P; Nominé Y; Masson M; Charbonnier S; Ramirez-Ramos JR; Deryckere F; Travé G; Orfanoudakis G
PLoS One; 2011; 6(10):e25981. PubMed ID: 22046250
[TBL] [Abstract][Full Text] [Related]
8. The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain.
Mansur CP; Marcus B; Dalal S; Androphy EJ
Oncogene; 1995 Feb; 10(3):457-65. PubMed ID: 7845670
[TBL] [Abstract][Full Text] [Related]
9. Sodium arsenite suppresses human papillomavirus-16 E6 gene and enhances apoptosis in E6-transfected human lymphoblastoid cells.
Chou RH; Huang H
J Cell Biochem; 2002; 84(3):615-24. PubMed ID: 11813266
[TBL] [Abstract][Full Text] [Related]
10. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation.
Crook T; Tidy JA; Vousden KH
Cell; 1991 Nov; 67(3):547-56. PubMed ID: 1657399
[TBL] [Abstract][Full Text] [Related]
11. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells.
Hengstermann A; Linares LK; Ciechanover A; Whitaker NJ; Scheffner M
Proc Natl Acad Sci U S A; 2001 Jan; 98(3):1218-23. PubMed ID: 11158620
[TBL] [Abstract][Full Text] [Related]
12. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding.
Midgley CA; Lane DP
Oncogene; 1997 Sep; 15(10):1179-89. PubMed ID: 9294611
[TBL] [Abstract][Full Text] [Related]
13. Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein.
Liu WL; Midgley C; Stephen C; Saville M; Lane DP
J Mol Biol; 2001 Nov; 313(4):711-31. PubMed ID: 11697899
[TBL] [Abstract][Full Text] [Related]
14. CTS1: a p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties.
Conseiller E; Debussche L; Landais D; Venot C; Maratrat M; Sierra V; Tocque B; Bracco L
J Clin Invest; 1998 Jan; 101(1):120-7. PubMed ID: 9421473
[TBL] [Abstract][Full Text] [Related]
15. Regulation of Mdm2-directed degradation by the C terminus of p53.
Kubbutat MH; Ludwig RL; Ashcroft M; Vousden KH
Mol Cell Biol; 1998 Oct; 18(10):5690-8. PubMed ID: 9742086
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus oncoprotein E6 binds to the C-terminal region of human minichromosome maintenance 7 protein.
Kukimoto I; Aihara S; Yoshiike K; Kanda T
Biochem Biophys Res Commun; 1998 Aug; 249(1):258-62. PubMed ID: 9705868
[TBL] [Abstract][Full Text] [Related]
17. Escape of p53 protein from E6-mediated degradation in HeLa cells after cisplatin therapy.
Wesierska-Gadek J; Schloffer D; Kotala V; Horky M
Int J Cancer; 2002 Sep; 101(2):128-36. PubMed ID: 12209989
[TBL] [Abstract][Full Text] [Related]
18. N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation.
Leng P; Brown DR; Shivakumar CV; Deb S; Deb SP
Oncogene; 1995 Apr; 10(7):1275-82. PubMed ID: 7731677
[TBL] [Abstract][Full Text] [Related]
19. Expansion of protein interaction maps by phage peptide display using MDM2 as a prototypical conformationally flexible target protein.
Burch L; Shimizu H; Smith A; Patterson C; Hupp TR
J Mol Biol; 2004 Mar; 337(1):129-45. PubMed ID: 15001357
[TBL] [Abstract][Full Text] [Related]
20. High-risk HPV E6 oncoproteins assemble into large oligomers that allow localization of endogenous species in prototypic HPV-transformed cell lines.
García-Alai MM; Dantur KI; Smal C; Pietrasanta L; de Prat-Gay G
Biochemistry; 2007 Jan; 46(2):341-9. PubMed ID: 17209544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
